Epilepsy. Episodic and paroxysmal disorders
Conditions
Interventions
This intervention is conducted, without control group, and the same patients suffering from intractable epilepsy are studied prior to and after being fed with the Ketocal formula.
The volume of the fo
Treatment - Other
This intervention is conducted, without control group, and the same patients suffering from intractable epilepsy are studied prior to and after being fed with the Ketocal formula.
The volume of the f
Sponsors
NUTRICIA
Eligibility
Sex/Gender
All
Age
12 Months to 5 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Having seizures which are intractable with at least two anti-epileptic medications, and having seizures once in every month, on average, in the last year; having no contraindication in respect of Ketogenic diet based on the reviewed sources. Exclusion criteria: Acute complications due to the treatment, leading to withholding the treatment.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Seizure frequency. Timepoint: Before intervention and during intervention. Method of measurement: Average of sezure frequency per week. | — |
Secondary
| Measure | Time frame |
|---|---|
| Toerability to ketocal diet. Timepoint: During intervention. Method of measurement: Descriptional.;Blood lipid profile(cholestrol, teriglyceride, LDL, HDL). Timepoint: At biginning and end of intervention. Method of measurement: Blood sampling and laboratory measurement.;Blood calcium. Timepoint: At biginning and end of intervention. Method of measurement: Blood sampling and laboratory measurement.;Serum vitamine 25 hydroxy vitamine D. Timepoint: At biginning and end of intrvention. Method of measurement: Blood sampling and laboratory measurement.;Side effects. Timepoint: Durin intervention. Method of measurement: Parents report.;Serum zinc. Timepoint: At biginning and end of interventon. Method of measurement: Blood sampling and laboratory measurement.;Blood glucose. Timepoint: At biginning and end of intervention and when the patient feels weakness. Method of measurement: Blood sampling and laboratory measurement and glucometery.;Blood alkalyn phosphatase. Timepoint: At biginning and end of intervention. Method of measurement: Blood sampling and laboratory measurement.;Blood urea. Timepoint: At biginning and end of intervention. Method of measurement: Blood sampling and laboratory measurement.;Plasma creatinine. Timepoint: At biginning and end of intervention. Method of measurement: Blood sampling and laboratory measurement. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Ahmad Hosseini
Tehran University of Medical Sciences
Outcome results
None listed